LENZ Therapeutics (LENZ) Operating Expenses (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Operating Expenses data on file, last reported at $46.0 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 171.9% year-over-year to $46.0 million in Q1 2026; TTM through Mar 2026 was $139.3 million, a 134.35% increase from a year earlier, with the FY2025 full-year figure at $110.2 million, up 88.07% from the prior year.
• Operating Expenses for Q1 2026 stood at $46.0 million, up from $40.1 million in the prior quarter.
• Over the last five years, Operating Expenses for LENZ reached as high as $46.0 million in Q1 2026 and fell as low as $12.6 million in Q1 2023.
• Historically, Operating Expenses has averaged $23.1 million across 5 years, with a median of $21.9 million in 2025.
• Across the five-year window, Operating Expenses soared 177.09% in 2022 and plunged 51.4% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $26.8 million in 2022, then slipped by 6.59% to $25.0 million in 2023, then plunged by 39.07% to $15.2 million in 2024, then soared by 163.06% to $40.1 million in 2025, then increased by 14.94% to $46.0 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $46.0 million in Q1 2026, $40.1 million in Q4 2025, and $31.4 million in Q3 2025.